在检查点抑制剂治疗期间使用bDMARD或tsDMARD管理炎症性关节炎的观察性研究
该多中心回顾性观察研究纳入20例在免疫检查点抑制剂(ICI)治疗下发生炎症性关节炎并接受bDMARD或JAK抑制剂治疗的患者,抗IL-6R治疗最常用(13/20,65%),临床改善11/13(85%),但1例发生肠穿孔,6/13(46%)出现癌症进展;TNF抑制剂用于5/20(25%),改善4/5(80%),癌症进展3/5(60%);bDMARD或JAK抑制剂中位使用17周,总体约半数患者出现癌症进展,其对肿瘤反应的影响尚待确定。
要点
- 抗IL-6R治疗是ICI诱导炎症性关节炎在糖皮质激素和甲氨蝶呤反应不足后最常用策略,改善率>80%。
- 抗IL-6R治疗中1例发生肠穿孔,6/13(46%)观察到癌症进展。
- TNF抑制剂治疗5例中4例改善,3/5(60%)观察到癌症进展。
核心结论
- 抗IL-6R治疗是目前ICI诱导炎症性关节炎在糖皮质激素和甲氨蝶呤反应不足时最常用的策略,改善率>80%。
- 总体约半数患者出现癌症进展,bDMARD或JAK抑制剂是否影响肿瘤反应尚待确定。
研究设计与样本
- 利用法国Club Rhumatismes and Inflammation网络开展的多中心、回顾性、观察性研究。
- 纳入20例在ICI治疗下诊断为炎症性关节炎并接受bDMARD或JAK抑制剂治疗的癌症患者。
- 采用标准化病例报告表收集临床数据。
主要发现
- 20例患者中男性60%,中位年龄69.5岁,类风湿关节炎样16例、风湿性多肌痛样2例、银屑病关节炎样2例,2例有既往类风湿关节炎。
- 90%以糖皮质激素为一线治疗,60%在bDMARD或JAK抑制剂前接受甲氨蝶呤。
- 抗IL-6R治疗用于13/20例(65%),11/13例(85%)临床改善,1例发生肠穿孔,6/13例(46%)观察到癌症进展。
- TNF抑制剂用于5/20例(25%),4/5例(80%)改善,3/5例(60%)观察到癌症进展,报告2例感染(憩室炎和肺炎)。
- 阿那白滞素、巴瑞替尼和乌司奴单抗各用于1例患者,bDMARD或JAK抑制剂中位使用17周。
局限性
- 原文结论指出bDMARD或JAK抑制剂是否影响肿瘤反应尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting. METHODS: Using the Club Rhumatismes and Inflammation French network, we conducted a multicentre, retrospective, observational study of patients with cancer diagnosed with inflammatory arthritis under ICI(s) and treated with bDMARD or JAKi. Clinical data were collected using a standardised case report form. RESULTS: Twenty patients (60% men, median age 69.5 years) were included, with rheumatoid arthritis (RA)-like (n=16), polymyalgia rheumatica-like (n=2) or psoriatic arthritis-like (n=2) clinical presentation. Two patients had pre-existing RA. 90% were treated with glucocorticoids as first-line therapy and 60% received methotrexate prior to bDMARD or JAKi. Anti-interleukin-6 receptor (IL-6R) therapy was used in 13/20 patients (65%), leading to clinical improvement in 11/13 patients (85%), but one patient experienced intestinal perforation and cancer progression was noticed in 6/13 patients (46%). Tumour necrosis factor inhibitors were used in 5/20 patients (25%), with improvement in 4/5 patients (80%) and cancer progression was observed in 3/5 patients (60%). Two infections (diverticulitis and pneumonitis) were reported. Anakinra, baricitinib and ustekinumab were each used in one patient. Median duration of the bDMARD or JAKi was 17 weeks. CONCLUSION: Anti-IL-6R therapy is currently the most common strategy in patients with ICI-induced inflammatory arthritis and insufficient response to glucocorticoids and methotrexate, leading to improvement in >80%. Overall, cancer progression occurred in about half of patients and whether the bDMARD/JAKi impacted the tumour response remains to be determined.
引用
- De La Fuente F, Belkhir R, Henry J, et al. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022. PMID: 36270747. doi:10.1136/rmdopen-2022-002612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。